Valuation: Xencor, Inc.

Market Cap 1.5B 1.3B 1.21B 1.11B 2.1B 143B 2.13B 14.29B 5.61B 71.21B 5.63B 5.5B 239B P/E 2026 *
-5.3x
P/E 2027 * -6.45x
Enterprise Value 1.5B 1.3B 1.21B 1.11B 2.1B 143B 2.13B 14.29B 5.61B 71.21B 5.63B 5.5B 239B EV / Sales 2026 *
19.5x
EV / Sales 2027 * 12.8x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day-5.96%
1 week+3.96%
1 month+31.40%
3 months+59.26%
6 months+67.16%
Current year+32.01%
1 week 19.04
Extreme 19.04
21.76
1 month 14.38
Extreme 14.38
21.76
Current year 10.38
Extreme 10.375
21.76
1 year 6.92
Extreme 6.92
21.76
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap.
16/6/26 Free

Director

30,906 0.0417%
23/1/26 Fiscal year

Chief Technology Officer

10,644 0.0149%
19/12/25 Fiscal year

Chief Technology Officer

232,723 0.3259%
Change 5-day change 1-year change 3-year change Capi.($)
-5.96%+3.96%+153.26%-15.90% 1.5B
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.71%-3.02%+47.61%+137.74% 23.54B
Weighted average by Cap. +0.19%-2.92%+31.57%+115.99%

Financials

2026 *2027 *
Net sales 76.73M 66.7M 62.09M 57M 108M 7.32B 109M 732M 287M 3.65B 288M 282M 12.23B 117M 102M 94.95M 87.18M 165M 11.2B 167M 1.12B 439M 5.58B 441M 431M 18.7B
Net income -303M -263M -245M -225M -425M -28.9B -431M -2.89B -1.13B -14.39B -1.14B -1.11B -48.24B -280M -243M -227M -208M -393M -26.73B -399M -2.67B -1.05B -13.31B -1.05B -1.03B -44.62B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
31/07/26 USD 20.21 -5.96% 1,318,724
30/07/26 USD 21.49 +10.04% 1,615,605
29/07/26 USD 19.53 -2.20% 1,161,148
28/07/26 USD 19.97 +0.55% 845,863
27/07/26 USD 19.86 +2.16% 942,303
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.21USD
Average target price
28.33USD
Spread / Average Target
+40.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock